Embrex filed a patent suite on Wednesday against a New Jersey firm, saying the company “infringed” on its in-ovo (in egg) injection system.
The suit, filed in federal court, seeking “injunctive relief and monetary damages” from AviTech of Hebron, MD. Embrex said it also wanted a jury trial.
“Invention is a critical component of our business strategy, and we are proud of the success we’ve had in patenting what we have discovered, designed and commercialized,” said Randall Marcuson, president and chief executive officer of Embrex, in a statement. “As The In Ovo Company(R), we will not allow others to infringe upon our patents. As we’ve done in the past, we will defend our intellectual property portfolio against any infringement so that we may protect our investment and that of our shareholders.”